Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Cash from Financing Activities (2020 - 2025)

Greenwich LifeSciences filings provide 5 years of Cash from Financing Activities readings, the most recent being $3.4 million for Q3 2025.

  • Quarterly Cash from Financing Activities rose 183.82% to $3.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $6.6 million through Sep 2025, up 54.82% year-over-year, with the annual reading at $4.4 million for FY2024, N/A changed from the prior year.
  • Cash from Financing Activities hit $3.4 million in Q3 2025 for Greenwich LifeSciences, up from $2.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $3.4 million in Q3 2025 and bottomed at -$5.5 million in Q1 2022.
  • Average Cash from Financing Activities over 4 years is $556556.3, with a median of $562596.0 recorded in 2021.
  • The largest annual shift saw Cash from Financing Activities tumbled 342.59% in 2022 before it soared 183.82% in 2025.
  • Greenwich LifeSciences' Cash from Financing Activities stood at $562596.0 in 2021, then crashed by 459.5% to -$2.0 million in 2022, then surged by 106.02% to $121829.0 in 2024, then surged by 2652.31% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Cash from Financing Activities are $3.4 million (Q3 2025), $2.6 million (Q2 2025), and $492423.0 (Q1 2025).